NO20051852L - Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer. - Google Patents

Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer.

Info

Publication number
NO20051852L
NO20051852L NO20051852A NO20051852A NO20051852L NO 20051852 L NO20051852 L NO 20051852L NO 20051852 A NO20051852 A NO 20051852A NO 20051852 A NO20051852 A NO 20051852A NO 20051852 L NO20051852 L NO 20051852L
Authority
NO
Norway
Prior art keywords
compounds
tgf
growth factor
transforming growth
inhibitors
Prior art date
Application number
NO20051852A
Other languages
English (en)
Norwegian (no)
Inventor
Michael John Munchhof
Laura Cook Blumberg
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20051852L publication Critical patent/NO20051852L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20051852A 2002-09-18 2005-04-15 Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer. NO20051852L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41213102P 2002-09-18 2002-09-18
US48458003P 2003-07-02 2003-07-02
PCT/IB2003/004005 WO2004026865A1 (fr) 2002-09-18 2003-09-12 Nouveaux composes d'isothiazole et d'isoxazole utilises comme inhibiteurs du facteur de croissance transformant (tgf)

Publications (1)

Publication Number Publication Date
NO20051852L true NO20051852L (no) 2005-06-16

Family

ID=32033584

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051852A NO20051852L (no) 2002-09-18 2005-04-15 Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer.

Country Status (25)

Country Link
US (1) US7030125B2 (fr)
EP (1) EP1542995A1 (fr)
JP (1) JP2006506443A (fr)
KR (1) KR20050057441A (fr)
CN (1) CN1681809A (fr)
AP (1) AP2005003262A0 (fr)
AR (1) AR041275A1 (fr)
AU (1) AU2003263431A1 (fr)
BR (1) BR0314286A (fr)
CA (1) CA2499332A1 (fr)
CO (1) CO5550458A2 (fr)
EA (1) EA200500286A1 (fr)
EC (1) ECSP055685A (fr)
HR (1) HRP20050246A2 (fr)
IS (1) IS7695A (fr)
MA (1) MA27444A1 (fr)
MX (1) MXPA05002378A (fr)
NO (1) NO20051852L (fr)
OA (1) OA12925A (fr)
PA (1) PA8583101A1 (fr)
PE (1) PE20050076A1 (fr)
PL (1) PL375973A1 (fr)
TW (1) TW200410954A (fr)
UY (1) UY27983A1 (fr)
WO (1) WO2004026865A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2323421T3 (es) 2002-09-18 2009-07-15 Pfizer Products Inc. Nuevos compuestos de oxazol como inhibidores del factor de crecimientotransformador (tgf).
CA2498047C (fr) * 2002-09-18 2009-05-19 Pfizer Products Inc. Composes d'imidazole utilises en tant qu'inhibiteurs du facteur de croissance transformant (tgf)
ES2335099T3 (es) * 2002-09-18 2010-03-22 Pfizer Products Inc. Novedosos compuestos de pirazol como inhibidor del factor de crecimiento transformante (tgf).
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
CA2580844A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant que modulateurs de stearoyle-coa desaturase
CA2580856A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
CN101083994A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途
WO2006034279A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
CN101083993A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
JP5123671B2 (ja) 2005-02-17 2013-01-23 シンタ ファーマシューティカルズ コーポレーション 増殖性疾患の治療のための化合物
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
AU2006325706B2 (en) * 2005-12-16 2012-03-29 Novartis Ag Control of intraocular pressure using ALK5 modulation agents
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
CA2935392C (fr) 2014-01-01 2022-07-26 Medivation Technologies, Inc. Derives de pyridine aminee pour le traitement de conditions associees a une activite excessive de tgf-.beta.
US10568883B2 (en) 2014-09-03 2020-02-25 Massachusetts Institute Of Technology Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP3400286A1 (fr) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Production de cellules entéroendocrines différenciées et cellules produisant de l'insuline
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
DK3429603T3 (da) 2016-03-15 2022-03-14 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller
CA3048220A1 (fr) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. Composes 1h-pyrrole-2,5-dione et leurs procedes d'utilisation pour induire un auto-renouvellement de cellules de support souches/progenitrices
EP3768267A4 (fr) 2018-03-20 2022-04-20 Icahn School of Medicine at Mount Sinai Composés inhibiteurs de kinase, compositions et procédés d'utilisation
WO2019236766A1 (fr) 2018-06-06 2019-12-12 Ideaya Biosciences, Inc. Procédés de culture et/ou d'expansion de cellules souches et/ou de cellules progénitrices engagées dans une lignée à l'aide de composés lactames
WO2020037326A1 (fr) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions et méthodes pour produire des cellules ciliées par la régulation à la baisse de foxo
EP3837352A1 (fr) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions et méthodes pour générer des cellules ciliées par la régulation à la hausse de jag-1
JP2022515652A (ja) 2018-12-31 2022-02-21 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5095272A (fr) * 1973-12-24 1975-07-29
KR20010012808A (ko) 1997-05-22 2001-02-26 윌리암스 로저 에이 p38 키나아제로서 4-아릴-3(5)-헤테로아릴 치환 피라졸
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1169317B1 (fr) 1999-04-09 2003-01-15 SmithKline Beecham Corporation Triarylimidazoles
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2002225730A1 (en) 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Compounds
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20040097502A1 (en) * 2001-02-02 2004-05-20 Gellibert Francoise Jeanne Pyrazoles as tgf inhibitors
DE60203263T2 (de) * 2001-02-02 2006-02-09 Smithkline Beecham Corp. Pyrazolderivate gegen tgf überexprimierung
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AR040726A1 (es) 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento

Also Published As

Publication number Publication date
ECSP055685A (es) 2005-05-30
CA2499332A1 (fr) 2004-04-01
AP2005003262A0 (en) 2005-03-31
EA200500286A1 (ru) 2005-08-25
US7030125B2 (en) 2006-04-18
CO5550458A2 (es) 2005-08-31
IS7695A (is) 2005-02-14
EP1542995A1 (fr) 2005-06-22
PL375973A1 (en) 2005-12-12
PE20050076A1 (es) 2005-03-26
TW200410954A (en) 2004-07-01
WO2004026865A1 (fr) 2004-04-01
PA8583101A1 (es) 2004-04-23
HRP20050246A2 (en) 2005-10-31
MXPA05002378A (es) 2005-05-23
KR20050057441A (ko) 2005-06-16
US20040116473A1 (en) 2004-06-17
CN1681809A (zh) 2005-10-12
JP2006506443A (ja) 2006-02-23
MA27444A1 (fr) 2005-07-01
OA12925A (en) 2006-10-13
AU2003263431A1 (en) 2004-04-08
AR041275A1 (es) 2005-05-11
UY27983A1 (es) 2004-04-30
BR0314286A (pt) 2005-08-02

Similar Documents

Publication Publication Date Title
NO20051852L (no) Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer.
MXPA05008148A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf).
NO20050838L (no) Nye pyrazolforbindelser som transformerende vekstfaktor (TGF)-inhibitorer
WO2004026863A8 (fr) Nouveaux composes de triazole et d'oxazole, inhibiteurs du facteur de croissance transformant
BRPI0408251A (pt) compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
NO20051010L (no) Triazolderivater som transformerende vekst faktor (TGF) inhibitorer
NO20041041L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
SE9903760D0 (sv) New compounds
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
NO20021728D0 (no) Pyrimidin-derivater
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
SE9903544D0 (sv) Novel compounds
BRPI0407055A (pt) Derivados de isotiazol
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
MEP42908A (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
HUP0202692A2 (hu) Interleukin-5 inhibitor hatású 6-azauracil-származékok, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik
ATE410148T1 (de) Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
AP9801417A0 (en) Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders.
HUP0303181A2 (hu) 4-Foszfodiészteráz típusú inhibitorok alkalmazása miokardiális betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
HUP0402654A2 (hu) 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten
ATE245151T1 (de) Diphenyl-1,2,3-thiadiazol-3-oxide, zusammensetzungen und verfahren zur anwendung
TH54252A3 (th) อนุพันธ์ไพราโซล ที่ถูกเข้าแทนที่ตัวใหม่